Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Revolution Medicines, Inc. (RVMD)

20.92   -0.19 (-0.9%) 03-24 16:00
Open: 21.02 Pre. Close: 21.11
High: 21.06 Low: 20.27
Volume: 1,117,357 Market Cap: 2,221(M)

Technical analysis

as of: 2023-03-24 4:29:29 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 29.1     One year: 32.86
Support: Support1: 19.7    Support2: 16.39
Resistance: Resistance1: 24.91    Resistance2: 28.13
Pivot: 22.26
Moving Average: MA(5): 21.21     MA(20): 23.01
MA(100): 23.78     MA(250): 21.82
MACD: MACD(12,26): -1.1     Signal(9): -1
Stochastic oscillator: %K(14,3): 20.2     %D(3): 21
RSI: RSI(14): 37.5
52-week: High: 31.37  Low: 14.07
Average Vol(K): 3-Month: 1,269 (K)  10-Days: 1,342 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ RVMD ] has closed above bottom band by 23.5%. Bollinger Bands are 3.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 21.09 - 21.19 21.19 - 21.29
Low: 19.97 - 20.1 20.1 - 20.22
Close: 20.68 - 20.89 20.89 - 21.09

Company Description

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Headline News

Fri, 24 Mar 2023
Revolution Medicines, Inc. (NASDAQ:RVMD) Receives Average ... - MarketBeat

Mon, 13 Mar 2023
$140M Bet On Southwest Gas? Check Out These 4 Stocks Insiders ... - UK

Sun, 12 Mar 2023
Hsbc Holdings PLC Invests $204000 in Revolution Medicines, Inc ... - MarketBeat

Sat, 11 Mar 2023
Revolution Medicines, Inc. (NASDAQ:RVMD) Q4 2022 Earnings Call Transcript - Yahoo Finance

Wed, 08 Mar 2023
Revolution Medicines, Inc. (NASDAQ:RVMD) Stake Cut by Polar ... - MarketBeat

Tue, 28 Feb 2023
Dentsply Sirona, Chico's FAS, Kontoor Brands And Other Big Stocks ... - UK

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 89 (M)
Shares Float 72 (M)
% Held by Insiders 1.4 (%)
% Held by Institutions 106.1 (%)
Shares Short 7,170 (K)
Shares Short P.Month 8,130 (K)

Stock Financials

EPS -2.39
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 8.65
Profit Margin (%) 0
Operating Margin (%) -845.5
Return on Assets (ttm) -20
Return on Equity (ttm) -37.2
Qtrly Rev. Growth 204.8
Gross Profit (p.s.) -1.78
Sales Per Share 0.33
EBITDA (p.s.) -2.77
Qtrly Earnings Growth 0
Operating Cash Flow -202 (M)
Levered Free Cash Flow -113 (M)

Stock Valuations

PE Ratio -8.79
PEG Ratio 0
Price to Book value 2.41
Price to Sales 62.94
Price to Cash Flow -9.21

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.